Liu Tingting, He Zhijiang, Lv Witiao, Deng Liyun, Sun Xizhe, Chen Yanfei
School of Hainan Provincial Drug Safety Evaluation Research Center, Hainan Medical University, Haikou, China.
Department of Orthopedics, Hainan Provincial Corps Hospital of Chinese People's Armed Police Force, Haikou, China.
J Anal Methods Chem. 2025 May 5;2025:2948965. doi: 10.1155/jamc/2948965. eCollection 2025.
The Feng-Liao-Chang-Wei-Kang (FLCWK) capsule is a nationally protected Chinese patent medicine for the treatment of colitis. However, the potential active components and the pharmacological mechanism underlying the anticolitis effect of the FLCWK capsule remain unclear. This study aimed to reveal the active ingredients and possible anticolitis mechanism of the FLCWK capsule using an integrated approach combining mass spectrometry and network pharmacology analysis. Ultra-performance liquid chromatography plus Q-Exactive Orbitrap tandem mass spectrometry (UPLC-Q-Exactive Orbitrap MS) was applied to identify the components of the FLCWK capsule. A network pharmacology study, including target gene prediction and functional enrichment, was applied to screen the active ingredients of the FLCWK capsule and explore its potential mechanism for the treatment of colitis. A total of 115 components were identified in the FLCWK capsule. Network pharmacology results showed that 46 of these compounds with good bioavailability and drug-likeness, such as 4',5-dihydroxyflavone, pinostrobin, naringenin chalcone, apigenin, and morin, were selected as active ingredients. The active ingredients may act on 352 core protein targets, including EGFR, AKT1, PIK3R1, PIK3CB, and MAPK1, thereby modulating relevant pathways, such as MAPK and PI3K-Akt signaling pathways, and thus alleviating inflammation and intestinal damage in colitis. This study provided a useful approach to identify active components and the anticolitis mechanism of the FLCWK capsule and built up a reliable foundation for its clinical treatment.
枫蓼肠胃康胶囊是一种治疗结肠炎的国家保护专利中药。然而，枫蓼肠胃康胶囊抗结肠炎作用的潜在活性成分和药理机制仍不清楚。本研究旨在采用质谱和网络药理学分析相结合的综合方法，揭示枫蓼肠胃康胶囊的活性成分和可能的抗结肠炎机制。应用超高效液相色谱-Q-Exactive轨道阱串联质谱（UPLC-Q-Exactive Orbitrap MS）鉴定枫蓼肠胃康胶囊的成分。通过网络药理学研究，包括靶基因预测和功能富集，筛选枫蓼肠胃康胶囊的活性成分，并探讨其治疗结肠炎的潜在机制。在枫蓼肠胃康胶囊中总共鉴定出115种成分。网络药理学结果表明，其中46种具有良好生物利用度和类药性的化合物，如4',5-二羟基黄酮、松属素、柚皮素查耳酮、芹菜素和桑色素，被选为活性成分。这些活性成分可能作用于352个核心蛋白靶点，包括表皮生长因子受体（EGFR）、蛋白激酶B1（AKT1）、磷脂酰肌醇-3激酶调节亚基1（PIK3R1）、磷脂酰肌醇-3激酶催化亚基β（PIK3CB）和丝裂原活化蛋白激酶1（MAPK1），从而调节相关通路，如丝裂原活化蛋白激酶（MAPK）和磷脂酰肌醇-3激酶-蛋白激酶B（PI3K-Akt）信号通路，进而减轻结肠炎中的炎症和肠道损伤。本研究为鉴定枫蓼肠胃康胶囊的活性成分和抗结肠炎机制提供了一种有用的方法，并为其临床治疗奠定了可靠的基础。
